Other News

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced a $50M Series B funding round led by Johnson & Johnson Innovation – JJDC, Inc. joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, […]

Top TeleRad Provider Aligned Radiology Selects InsiteOne, NewVue, and RADPAIR to Deliver Cloud-Native PACS, AI-Powered Workflow Orchestration, and Conversational Generative AI Diagnostic Reporting

WALLINGFORD, Conn. and TAMPA, Fla., Sept. 11, 2024 /PRNewswire/ — InsiteOne, NewVue.AI, and RADPAIR are thrilled to announce a groundbreaking strategic contract with Aligned Radiology, a leading teleradiology provider. This collaboration combines advanced AI-driven workflow…

Merit Medical to Present at the 2024 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Congress

SOUTH JORDAN, Utah, Sept. 11, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that clinicians will present updates on two of its pivotal studies during scientific sessions held on September 14 at CIRSE in Lisbon, Portugal.

Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O’Neil as Chief Financial Officer and Erin Lavelle as Director

– Company continuing to advance clinical development of HU6, a novel oral, once-daily Controlled Metabolic Accelerator, in Phase 2 trials to treat obesity-related heart failure and metabolic dysfunction-associated steatohepatitis (MASH) – CHARLOTTESVILLE, Va. and SAN FRANCISCO, Sept. 11,…

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

HeartBeam Names Timothy Cruickshank as Chief Financial Officer

SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Timothy Cruickshank as Chief Financial Officer (CFO), effective immediately. Mr. Cruickshank brings more than 15 years of public company experience with […]

The Case for Integrating Novel Device-Based Therapies into Guideline Directed Medical Therapy for the Treatment of Heart Failure

WASHINGTON, Sept. 10, 2024 /PRNewswire/ — Novel device-based therapies may overcome limitations of pharmacologic therapies for some patients living with heart failure (HF), indicating that a synergistic approach between the two therapies is ideal for implementation of guideline directed…

CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients

BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow’s initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate. “The improvement in […]